Glenmark Pharma launches drug for treatment of Type 2 diabetes in adults – Moneycontrol

My Account
Follow us on:
Powered By
Learn, discover & invest in smallcases across different types to build your long term portfolio.
Invest Now
Explore from India`s leading investment managers and advisors curating their strategies as smallcases.
Invest Now
Powered By
Diversify your portfolio by investing in Global brands.
Invest Now
Pre-configured baskets of stocks & ETFs that you can invest
in with a single click. Developed by hedge funds, global
asset management companies, experienced wealth
management firms and portfolio managers.
Invest Now

AMBAREESH BALIGA
Fundamental, Stock Ideas, Multibaggers & Insights
Subscribe
CK NARAYAN
Stock & Index F&O Trading Calls & Market Analysis
Subscribe
SUDARSHAN SUKHANI
Technical Call, Trading Calls & Insights
Subscribe
T GNANASEKAR
Commodity Trading Calls & Market Analysis
Subscribe
MECKLAI FINANCIALS
Currency Derivatives Trading Calls & Insights
Subscribe
SHUBHAM AGARWAL
Options Trading Advice and Market Analysis
Subscribe
MARKET SMITH INDIA
Model portfolios, Investment Ideas, Guru Screens and Much More
Subscribe
TraderSmith
Proprietary system driven Rule Based Trading calls
Subscribe


Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Subscribe
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Explore
STOCK REPORTS BY THOMSON REUTERS
Details stock report and investment recommendation
Subscribe
POWER YOUR TRADE
Technical and Commodity Calls
Subscribe
INVESTMENT WATCH
Set price, volume and news alerts
Subscribe
STOCKAXIS EMERGING MARKET LEADERS
15-20 High Growth Stocks primed for price jumps
Subscribe
Glenmark Pharmaceuticals on October 6 announced that it has become the first company in India to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) for the treatment of Type 2 diabetes in adults.
The drug is being marketed under the brand name LOBG, contains Lobeglitazone (0.5 millgrams) and is to be taken once daily under prescription to improve glycemic control in adult diabetic patients, the company said in a statement.
According to Glenmark, Indians have a high prevalence of what can be termed as ‘insulin resistance’, thus LOBG is a viable option for controlling Type 2 diabetes among insulin‐resistant diabetic patients. Data collected by the International Diabetes Federation suggests every four out of ten diabetic patients seem to have insulin resistance in India.
The Drug Controller General of India (DCGI) gave the pharma company approval to manufacture and market Lobeglitazone based on a randomized, double‐blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of this trial showed that patient on LOBG had a faster and improved glycemic control.
Also Read: India among top ten countries with highest Type 2 diabetes prevalence: Lancet study
Commenting on the launch of the drug Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals, said,
“As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40% of them seem to be insulin‐resistant. As a leading solutions provider in India for the treatment of diabetes, we are proud to introduce LOBG; an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.”
Also Read: COVID-19 linked with higher risk of type 1 diabetes in young people: Study 
Health information technology and clinical research company IQVIA found that in the sales data for the 12‐month period ending Aug. 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs 11,725 crore with an annual growth of 7% against the corresponding period last year.
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.

source